Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Growing
The company is in a growing phase, with the latest annual income totaling USD 86.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 86.55M.
Fairly Valued
The company’s latest PE is -2.85, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.44M shares, decreasing 15.49% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.